Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited
Mandate

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

November 19, 2024 M&A Intellectual Property Employment and Benefits

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.

Semmco Group designs and manufactures products that enable safe and efficient maintenance of airplanes, helicopters, and trains. The product range includes specially developed access platforms, steps and docking systems. The customers are primarily international aviation and train companies. Semmco's headquarters and main manufacturing operation are located in Woking, Surrey, England. Manufacturing and sales operation also take place in Arlington, Texas, USA. The markets in the Middle East and Asia are served through a sales office in Dubai, United Arab Emirates.

Vinge's team consisted of Anna Edström, Niklas Törnell, Johan Severinsson (M&A), as well as Lisa Bourghardt (IP) and Karin Hultgren (employment law/personal data).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025